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Background:  The  present  study  describes  an assessment  of a large-scale  intervention,  “Avahan”,  using  an
evaluation  framework  that  assesses  the  program  coverage,  changes  in  injection  patterns,  condom  use,
and STI and  HIV  prevalence  among  People  Who  Inject  Drugs  (PWID)  in  two  states  of India  –  Manipur  and
Nagaland.
Methods:  Program  monitoring  data  and  results  from  two  rounds  of  a cross  sectional  biological  and
behavioural  surveys  in  2006  (Round  1)  and  2009  (Round  2) were  used.  The  sample  included  839 and
860  PWIDs  from  Manipur  and  821  and  829  PWIDs  from  Nagaland  in  Round  1 and  Round  2 respectively
for  current  analysis.  Bivariate  and  multivariate  analyses  were  done  to measure  the changes  in behavioural
and biological  outcomes  between  the  two  rounds  and  to examine  the  association  between  programme
exposure  and  behavioural  outcomes.
Results:  In Manipur,  about  77%  of the  PWIDs  were  contacted  by  the  peer  educators/outreach  workers
every  month  and  about  18% of  the  PWIDs  visited  the clinic  every  month  by  March  2010.  In  Nagaland,
however,  the proportion  of PWIDs  visiting  the  clinic  monthly  remained  low  (11% in  March  2010).  PWIDs
in  both  states  were  more  likely  to report  ‘consistent  safe  injection  practice  in  the  last  six  months’  in
Round  2 compared  to Round  1 (Manipur:  adjusted  odds  ratio  (aOR):  1.88,  95%  conﬁdence  intervals  (CI):
1.46–2.43;  Nagaland:  aOR:  2.35,  95% CI: 1.86–2.80)  PWIDs  were  also  more  likely  to report  consistent
condom  use  with  regular  partners  in Round  2.  The  prevalence  of  Hepatitis  B virus (HBV)  increased  in
Round  2 in  Manipur  (11% vs  6%,  p <  0.001)  and  Nagaland  (8%  vs  6%,  p  = 0.05).  The  prevalence  of  Hepatitis
C virus  (HCV)  was  high  and  did  not  change,  either  in  Manipur  (67.3%  vs  69.9%, p = 0.42) and  Nagaland
(14.7%  vs  15.1%,  p  =  0.82).  Similarly,  the  prevalence  of  HIV  did  not  change  signiﬁcantly  between  the  two
Rounds  either  in  Manipur  (27.8%  in  Round  1 vs 29.2%  in Round  2, p  = 0.59)  or  in  Nagaland  (1.2% in Round
1  and 1.6%  in  Round  2 of  the  IBBA, p =  0.82).
Conclusion: Improvements  in safe  injection  practices  and  consistent  condom  use  with  regular  partners
suggest effectiveness  of  prevention  efforts.  However,  increase  in  HBV  prevalence  and  non-decline  in
HCV  and HIV  prevalence  in both  the  states  also  underscore  the  need  to  continue  and  intensify  targeted
interventions  (such  as Hepatitis  B  vaccination,  needle  exchange  programmes,  condom  distribution)  for
amonlong  term  risk reduction  
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Introduction
The HIV epidemic in India is concentrated among high-risk
groups like female sex workers (FSW) and their clients, sexually
transmitted infections (STI) clinic attendees, men  who  have sex
with men  (MSM), male-to-female transgendered people, and Peo-
ple Who  Inject Drugs (PWID). The recent HIV sentinel surveillance
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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010–2011 shows that HIV prevalence among antenatal clinic
ttendees (considered representative of the general population)
s low (0.4%), and that HIV prevalence is higher among the high
isk groups. According to the surveillance report, the prevalence
as 2.7% among FSWs, 4.4% among MSM,  and 7.1% among PWIDs;
hus, PWIDs have the highest HIV prevalence among the high risk
roups in India on average (National AIDS Control Organisation,
012). Furthermore, PWIDs are also at high risk of infection with
lood-borne viruses such as Hepatitis B and Hepatitis C (Horton
 Das, 2010). It has been reported that the prevalence of Hepati-
is B surface antigen was 3.8% and the prevalence of Hepatitis C
as as high as 47.8% (Mahanta, Borkakoty, Das, & Chelleng, 2009).
he National AIDS Control Organization (NACO) of India in its third
hase considers prevention interventions among PWIDs as a key
hrust area; thus, there is an emphasis on targeted interventions in
hese groups to encourage safe injecting practices (National AIDS
ontrol Organisation, 2012).
India, with a population of 1.2 billion, is a huge and diverse coun-
ry comprising of 28 states and seven union territories (National
ortal of India, 2014). In 2002, six states were considered to be high
revalence states. Of these, Manipur and Nagaland, the two north-
astern states were considered as high prevalence states (in 2002)
n India. The HIV epidemic in these states has largely been driven
y injecting drug use (Mahanta et al., 2009; Medhi et al., 2011;
ational AIDS Control Organisation, 2011). Injecting drug use is a
erious public health concern in both states, with approximately
% of the population engaging in injecting (Chandrasekaran et al.,
006), even though the nature of the types of drugs used in both the
tates may  differ. The estimated adult HIV prevalence was 1.4% in
anipur and 0.8% in Nagaland, and among PWIDs, the HIV preva-
ence was 12.9% in Manipur (2010–2011) and 2.2% in Nagaland
2010–2011) (National AIDS Control Organisation, 2012). Though
he HIV prevalence was very high in Manipur (about 80%) in late
ineties, it has reduced in the recent years (about 12%) in 2007.
In both these states, the respective State AIDS Control Soci-
ty (SACS) were the main funders of the HIV programmes and
nterventions and covered about 50–60% of PWIDs till 2003. “Ava-
an”, the India AIDS Initiative, supported by the Bill & Melinda
ates Foundation is considered to be one of the largest prevention
rogrammes in a single country. Initiated in 2003, it focussed on
revention programmes and targeted interventions in what was
onsidered to be a concentrated epidemic. The intervention pro-
rammes were started across various states in high risk groups
uch as female sex workers and their clients, men  who  have sex
ith men, and PWIDs; the population for interventions were based
n the nature of the epidemic and key populations in these states
Bertozzi, Padian, & Martz, 2010; Dandona & Benotsch, 2011; Laga &
uylsteke, 2011; Sgaier et al., 2012). It started interventions among
WIDs in certain selected districts in both Manipur and Naga-
and. These districts were selected in consultation with national
nd state level authorities, so as to avoid duplication of services
Fig. 1a and b). Avahan’s main strategies for intervention were:
o achieve a high coverage of services including outreach; deliver
 package of proven prevention services (provision of free new
eedle/syringe, abscess management, clinic services for treating of
exually transmitted infections, condom promotion and distribu-
ion and empowering the community); and address determinants
f HIV risk (sharing needle/syringe, condom use, multiple partners
nd advocacy to reduce structural barriers to safer injection and
ex practices) (Priya Mannava, Pillai, Hazarika, Chandrashekar, &
ermode, 2012).
Avahan’s evaluation framework was based on approaches forarge-scale public health programs and followed the program’s
ogic model: assess scale-up and coverage; changes in intermedi-
te outcomes (such as safe injecting practice [consistently avoiding
njection with a needle/syringe already used by others, drawingof Drug Policy 25 (2014) 853–864
drugs from common container], consistent condom use and reduc-
tion of STIs); and changes in HIV prevalence among the high risk
groups (Bill & Melinda Gates Foundation, 2008a, 2010; Boerma
& Weir, 2005). Two rounds of cross-sectional surveys termed
Integrated Behavioural and Biological Assessments (IBBA) were
conducted in 2006 and 2009 to assess these outcomes.
The present manuscript assesses the role of Avahan interven-
tion on changes in behaviours and HIV/STIs among male PWIDs
in Manipur and Nagaland. The speciﬁc objectives were: (1) to
document the scale-up and intensity of coverage of the Avahan
programme; (2) to study self-reported consistent safe injecting
practice and their association with the Avahan intervention; (3)
to estimate the association between self-reported consistent con-
dom use and Avahan intervention; and (4) to assess the prevalence
of STIs and blood-borne infections (including HIV, Hepatitis B, and
Hepatitis C) and their association with Avahan intervention.
Methods
This paper uses programme monitoring data, and behavioural
and biological data from two cross sectional surveys – the IBBA
surveys – conducted in Manipur and Nagaland.
Framework
We  developed an analytical evaluation framework based on the
Avahan evaluation design (Table 1). The aim of using the framework
was to: (1) examine the scale and intensity (based on availabil-
ity and utilization of services) of Avahan coverage; (2) assess the
intermediate outcomes-consistent safe injecting practice and con-
dom use; (3) assess changes in prevalence of STIs including HIV and
other blood borne pathogens; and (4) examine the association of
exposure to the Avahan interventions and self-reported injecting
behaviour, self-reported condom use, and STI prevalence.
Data sources
Avahan program monitoring data
Avahan developed a computerized management information
system (CMIS) which collected data on outreach services and
clinical services through the course of program implementation
(Verma et al., 2010). In each district, NGO partners implement-
ing the Avahan program gathered and reported monthly data on
program inputs and infrastructure, outreach services, and clin-
ical service utilization. Data were aggregated and reported to
the lead implementing partner at the state level and a subset
of indicators was aggregated centrally using the CMIS. Program
monitoring data from January 2005 till March 2011 were used
to assess trends of programme coverage and uptake of program
services.
Integrated Behavioural and Biological Assessment (IBBA)
Two rounds of IBBA were undertaken among male PWIDs in two
districts (Bishnupur and Churachandpur) of Manipur and two  dis-
tricts (Phek and Wokha) of Nagaland (Fig. 1a and b). These districts
were selected from seven Avahan intervention districts in Manipur
and eight in Nagaland; they were chosen purposively based on size
of the PWID population (Saidel et al., 2008). The size estimates of
PWIDs were 2000 in Bishnupur, 2400 in Churchandrapur, 2200 in
Phek, and 3100 in Wokha districts. In Manipur, Avahan’s cover-
age was 100% in Bishnupur, 87% in Churchandrapur, and 100% in
both the districts of Nagaland. Thus, Avahan was  the sole interven-
tion in three of the four districts of the IBBA and a signiﬁcant part
in the fourth district. Round 1 of the IBBA was conducted in 2006
and Round 2 in 2009. Men  aged 18 years or older who  reported
injecting drugs for non-medical reasons at least once in the last six
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Fig. 1. (a and b) Maps of Manipur and Nagaland – Districts where the Avahan intervention was implemented and districts from where the Integrated Behavioural and
Biological Assessment (IBBA) data were collected. Note: The coloured regions are the sites in which the Avahan intervention was  implemented and the spotted regions
indicate  the districts (among all Avahan intervention districts) from where the IBBA data were collected.
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Table 1
Evaluation framework, indicators and data sources used in analysis.
Research question Indicator Data source
1. Is coverage of Avahan
adequate?
A. Scale
a. Geographical coverage – Description of rollout in number of districts and change in number of
implementing NGOs over time and estimated populations covered by NGO
CMIS
b. Proportion of PWIDs ever contacted and ever visited clinic – Number of PWIDs ever contacted by Avahan
peer  educators or ever visited Avahan program STI clinics divided by the estimated size of PWIDs as of
June 2009
CMIS
c. Proportion of PWIDs contacted monthly by peer educators or visited program STI clinics for STI
consultations – Number of PWIDs contacted monthly by peer educators or visited program STI clinics
monthly divided by the estimated size of PWIDs as of June 2009
CMIS
d. Proportion of PWIDs contacted by Peer educator (PE)/Outreach worker (OW) and visited clinic in last month
–  Percentage of PWIDs from IBBA who  reported that they had been contacted by Avahan peer educators in
the  past month (Avahan NGOs)
IBBA
e. Proportion of PWIDs contacted by PE/OW and visited clinic in last year – Percentage of PWIDs from IBBA
who  reported that they had been contacted by Avahan peer educators in the year preceding survey
IBBA
B.  Intensity
a. Ratio of peer educator to the number of PWIDs covered – The total number of active outreach workers and
peer  educators in the Avahan intervention areas across implementation districts in Manipur and Nagaland;
and  number of estimated PWIDs covered per peer educator in the coverage area (target ratio was 1:50)
CMIS
b.  Needle/syringe distribution – Number of free needle/syringe distributed by Avahan programme per PWID
per  month
IBBA
2. Has there been an increase in
safe needle/syringe and condom
use among PWIDs?
Change in safe injecting behaviour and condom use pattern
a.  Proportion of PWIDs reporting safe injecting (did not inject with a needle previously used by someone
else)  last time from two rounds of IBBAs
IBBA
b. Proportion of PWIDs reporting safe injecting consistently from two  rounds of IBBAs IBBA
c.  Proportion of PWIDs reporting last time and consistent condom use with regular female partners from
two  rounds of IBBAs
IBBA
d. Proportion of PWIDs who had sex with female sex workers reporting last time and consistent condom
use  from two rounds of IBBAs
IBBA
3. Has there been reduction in
STIs, HIV and Hepatitis
prevalence?
Change in STI prevalence and visits to clinic with STI symptoms
STI  prevalence (reactive syphilis serology, gonorrhoea (NG), chlamydia (CT) IBBA
Change in HIV prevalence
HIV prevalence among PWIDs in two  rounds of IBBAs
Change in Hepatitis-B and Hepatitis-C prevalence
Hepatitis-B and Hepatitis-C prevalence among PWIDs in two  rounds of IBBAs IBBA
4.  Is Avahan exposure associated with
increase in safe injecting behaviour,
condom use and declining STIs?
Association of program exposure with intermediate outcomes and STIs
a. Avahan program exposures, deﬁned as exposure to any one of contacted by and Avahan peer educator,
visited Avahan program clinic, and received needle/syringe/condom from peer educators in past one year.
Its  association with consistent safe injecting practice and consistent condom use with sexual partners
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b. Program exposure, as deﬁned abov
serology or high-titre syphilis) and H
onths were recruited using respondent driven sampling (RDS),
 probability-based method of sampling for hidden populations.
ight seeds of diverse characteristics were recruited each from
anipur and ten seeds from Nagaland. Three coupons were dis-
ributed to each respondent for further distribution to the peers
s part of recruitment process. Both primary and secondary incen-
ives were provided to the respondents. The average network size
n Round 1 and Round 2 were respectively 11 and 9 in Manipur, 8
nd 7 in Nagaland. Data were collected from 839 (Round 1) and 821
Round 2) male PWID respondents in Manipur; 860 (Round 1) and
29 (Round 2) respondents in Nagaland. Both the rounds of IBBA
ollected behavioural information, dry blood spot (DBS – for detec-
ion of HIV, syphilis, Hepatitis B Virus [HBV], and Hepatitis C Virus
HCV]), and urine specimen (for detection of Neisseria gonorrhoea
NG] and Chlamydia trachomatis [CT]).
The ﬁeldwork was conducted by research agencies under the
uidance and supervision of Regional Medical Research Centre
RMRC), the State Institute of Indian Council of Medical Research
ICMR) in Assam, and in coordination with the National AIDS
esearch Institute (NARI). FHI 360 provided technical assistance to
onduct both rounds of the IBBA. Informed consent was  obtained
rom the respondents. The survey team was trained in question-
aire administration, sample collection, and transport of biological
amples. The IBBA data collection was approved by Protection of
uman Subjects Committee (FHI 360), Health Ministry Screening
ommittee (Indian Council for Medical Research), and the ethical its association with having any STI (NG, CT, reactive syphilis
is B and C
IBBA
committee of RMRC. Additional details of the IBBA methodology
have been discussed elsewhere (Bill & Melinda Gates Foundation,
2008b, 2010; Saidel et al., 2008).
Outcome variables
(i) Programme monitoring indicators from CMIS (Table 1) were
used to assess the scale-up, intensity, coverage, and access of
Avahan services.
(ii) Behavioural outcomes were self-reported consistent safe injec-
tion practice (deﬁned as never sharing needles/syringes with
another person) and self-reported consistent condom use
(deﬁned as using condom in every sex act).
iii) Biological outcomes were HIV, syphilis, HBV, and HCV from
blood specimens, and NG and CT from urine specimens. HIV
positivity was determined by a two-test algorithm using two
rapid tests (Microlisa-IV [J. Mitra & Co. Pvt. Ltd.] and Gene-
dia HIV ½ ELISA 3.0 [Greencross Life Sciences]). Nucleic acid
ampliﬁcation (Gen-Probe APTIMA COMBO 2 – Gen-Probe Inc.,
San Diego, CA) tests on urine samples were done for chlamy-
dia and gonorrhoea. Syphilis serology was  carried out using
Treponostika TP recombinant (BioMerieux), a solid phase
enzyme-linked immunoassay for testing anti-treponemal anti-
bodies using dry blood spot. HBsAg ELISA was carried out on
all DBS samples at the state laboratory using Murex HBsAg
Version 3 kits (Abbott Diagnostics) and antibodies against
urnal 
(
S
a
(
p
b
b
w
c
u
o
f
c
t
t
L
r
c
w
a
i
a
d
i
o
t
d
a
p
t
e
u
t
o
t
t
c
e
1
t
a
R
l
(
P
tP. Goswami et al. / International Jo
Hepatitis C were tested by Enzyme ImmunoAssay (Murex anti-
HCV Version 4.0, Abbott Diagnostics).
iv) A composite binary variable for exposure to Avahan inter-
vention was created using three parameters which included
the variables: (a) contact with peer educator; (b) received
needles/syringes from outreach workers; and (c) visited the
clinic/drop-in centre. If the response was ‘yes’ to any of the
three variables, the composite variable was  coded as exposed.
We examined the association between exposure to Avahan
intervention, and the biological and behavioural outcomes.
tatistical analyses
Data were analyzed and presented separately for Manipur
nd Nagaland. Descriptive analyses were done using RDSAT 5.6
Volz, Wejnert, Degani, & Heckathorn, 2007); we calculated the
roportions and conﬁdence intervals for the socio-demographics,
ehavioural variables, exposure to Avahan intervention, and
iological outcomes. The descriptive data represent population
eighted estimates. We  generated unique seed numbers and the
oupon numbers were reconstructed to carry out aggregate level
nivariate analysis using RDSAT at the state level for each round
f the IBBA. We  also checked and veriﬁed the equilibrium criteria
or the key variables using RDSAT 5.6. The individual weights are
alculated by the RDSAT; they are proportional to the inverse of
he respondent’s degree (their network size) and RDSAT generates
he weighted estimates by default (Heckathorn, 2007; Schonlau &
iebau, 2012).
SPSS Version 15.01 (IBM®, New York) was used to run logistic
egression models to measure the association between the out-
ome and explanatory variables. Weight of the dependent variable
as calculated using RDSAT and applied to carry out weighted
nalysis (Volz et al., 2007). The models were built in the follow-
ng sequence: (1) unadjusted associations between the exposure
nd the outcomes; and (2) multivariate models adjusted for age,
istrict of data collection, education, marital status, frequency of
njection in the past one month, duration of injecting, and round
f the IBBA. The ﬁrst set of logistic regression models estimated
he association between safe injection practices, consistent con-
om use, and biological variables (HIV, syphilis, Chlamydia, HBV,
nd HCV) as outcomes and the round of IBBA data collection as the
rimary explanatory variable (Table 3). For these analyses, both
he rounds were combined into a single dataset and the refer-
nce for each estimate was Round 1 of the IBBA. NG could not be
sed as an outcome measure for the logistic regression models as
he weights for NG could not be calculated due to the limitations
f the RDSAT software. The next set of logistic models estimated
he association between behavioural variables (self-reported injec-
ion practices, self-reported condom use, and HIV testing) and
omposite exposure to the Avahan intervention programmes as
xplanatory variable; these were analyzed separately for Rounds
 and 2 of IBBA (Table 4). We  compared the odds ratios in these
wo Rounds of the IBBA using the methods described by Altman
nd Bland (2003).
esults
We  have presented the results separately for Manipur and Naga-
and.
A) Manipurrogramme coverage data
CMIS data indicate that about 9% of the target PWID popula-
ion in Manipur (estimated to be 9600 in the Avahan catchmentof Drug Policy 25 (2014) 853–864 857
area in two districts) were registered in the Avahan intervention
by January 2005; this proportion increased to more than 80% by
September 2006 and remained so till March 2010. Less than 1% of
the PWID had ever visited the clinic by March 2005; however, this
proportion increased to about 58% by March 2010. About 77% of
the PWIDs were contacted by the peer educators/outreach work-
ers every month and about 18% of the PWIDs visited the clinic every
month by March 2010 (Fig. 2a). The ratio of peer educators to the
number of PWIDs was 1:93 in June 2005; this ratio changed to 1:52
by June 2008 which is close to Avahan target of 1:50 (Fig. 2b) (Verma
et al., 2010). About two free needles and syringes (free of cost) were
distributed per PWID/per month in June 2005 which increased to
17 per PWID/per month by March 2010. The return rate of needle
and syringes remained at 60–70% throughout.
The IBBA data also reﬂect this increase in the access to services.
About 47% of the PWIDs reported visits to clinics in Round 1 of
the IBBA; this proportion increased to 71% by Round 2 (p < 0.001).
There was  a statistically signiﬁcant increase in being contacted by
the Avahan peer educator in the Round 2 compared with Round 1
(54% vs 47%, p = 0.01) (Table 2).
Socio-demographic data
About 38% of PWIDs were in the age group of 21–25 years in
Round 1, whereas a high proportion of the PWIDs (36%) were more
than 31 years of age in Round 2 in Manipur. In general the pro-
portion of literate PWIDs was high in both the states and did not
differ signiﬁcantly in both rounds of the IBBA (Table 2). Even though
most of the PWIDs were not married in both Rounds, the propor-
tion of currently married PWIDs was signiﬁcantly higher in Round 2
compared with Round 1 (36% vs 26%, p < 0.001). Select demographic
characteristics of the PWIDs in Rounds 1 and 2 have been described
in Table 2.
Behavioural and biological data
Drug-injecting behaviours. The proportion of daily injectors was sig-
niﬁcantly higher in Round 2 compared with Round 1 (57% vs 48%,
p = 0.01). Similarly, the proportion of PWIDs who reported inject-
ing drugs for more than 5 years was  signiﬁcantly higher in Round 2
compared with Round 1 (48% vs 25%, p < 0.001) (Table 2). However,
PWIDs in Round 2 were more likely to report ‘consistent safe injec-
tion practice in the last six months’ (adjusted odds ratio [aOR] 1.88,
95% conﬁdence intervals [CI]: 1.46–2.43) and ‘safe injection during
the last injection’ (aOR: 3.83, 95% CI: 2.48–5.92). Similarly PWIDs
in Round 2 were more likely to use condom during the last sex act
with a female sex worker (aOR: 8.47, 95% CI: 2.28–31.43). We  found
that odds of drawing drugs from the same container during the last
episode of drug use among PWIDs who were exposed to the Ava-
han intervention was signiﬁcantly lower in Round 2 compared with
Round 1 (Round 2: aOR: 0.45, 95% CI: 0.33–0.62 vs Round 1: aOR:
1.61, 95% CI: 1.20–2.15; p < 0.01), however there were no signiﬁcant
difference in needle/syringe sharing behaviours (Table 4).
Condom use and other behaviours. PWIDs in Round 2 were more
likely to report consistent condom with a regular female partner
compared with Round 1 (aOR: 1.57, 95% CI: 1.11–2.23) (Table 3).
PWIDs exposed to Avahan interventions were more likely to use
condoms with regular female partners in Round 2 of the IBBA com-
pared with Round 1 (Table 4). A higher proportion of PWIDs in our
sample reported having undergone HIV testing in Round 2 com-
pared with Round 1 (38% vs 15%, p < 0.001), and those exposed to
the Avahan interventions were more likely to have had an HIV test
in both Rounds 1 and 2 compared with those not exposed to Avahan
interventions (Table 4).
STIs and blood-borne infections. The change in serological outcomes
did not follow a consistent pattern between the two  rounds of the
858 P. Goswami et al. / International Journal of Drug Policy 25 (2014) 853–864
Fig. 2. (a–c) Figures showing the scale and extent of coverage of different components of the Avahan programme for People Who  Inject Drugs (PWIDs) in Manipur and
Nagaland (2005–2010), India.
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Table  2
Descriptive statistics (demographics, injecting behaviours, condom use, exposure to the programme, and STIs including HIV) of among People Who  Inject Drugs (PWIDs) in
Manipur  and Nagaland, India.
Background characteristics Manipur Nagaland
IBBA Round 1 (95%, CI) IBBA Round 2 (95%, CI) p-Value IBBA Round 1 (95%, CI) IBBA Round 2 (95%, CI) p-Value
Demographic variables
Age
18–20 14.5 (11.5–17.5) 4.0 (2.5–5.5) <0.001 36.4 (32.0–40.7) 18.0 (14.4–20.8) <0.001
21–25  38.1 (34.2–42.1) 26.0 (22.5–29.7) <0.001 34.1 (31–38.0) 34.8 (31.5–38.9) 0.94
26–30  25.2 (21.9–28.8) 34.1 (30.6–37.4) <0.001 22.2 (19.4–25.5) 26.7 (23.5–38.9) 0.21
31–highest 22.2 (18.8–25.7) 35.9 (32.4–39.8) <0.001 6.8 (4.9–8.7) 20.5 (17.6–23.6) <0.001
Education
Literate 94.3 (92.3–95.7) 91.8 (89.7–93.4) 0.07 87.1 (84.8–89.5) 88.1 (85.9–90.3) 0.54
Marital status
Never married 69.0 (65.4–72.2) 51.8 (47.6–55.7) <0.001 83.3 (80.5–86.0) 66.4 (62.8–69.6) <0.001
Currently married 25.8 (22.0–29.0) 35.6 (32.2–39.7) <0.001 15.1 (12.4–17.6) 27.6 (24.5–31.1) <0.001
Divorced/widowed/separated 5.2 (4.0–7.0) 12.5 (10.1–15.0) <0.001 1.6 (0.9–2.5) 6.1 (4.4–7.6) <0.001
Injection practices
Duration of injecting drugs
Below 1 years 19.1 (15.3–23.3) 6.3 (4.5–8.6) <0.001 30.2 (26.0–34.5) 9.9 (7.5–11.6) <0.001
1–3  years 37.9 (34.7–41.6) 27.7 (23.8–31.3) <0.001 37.9 (34.7–41.6) 61.3 (57.8–65.1) <0.001
3–5  years 17.7 (15.1–20.4) 18.5 (15.7–21.3) 0.69 12.6 (10.7–14.9) 16.3 (13.8–18.7) 0.02
5+  years 25.3 (21.7–28.6) 47.6 (43.8–51.4) <0.001 21.2 (17.9–24.0) 12.5 (10.3–15.1) <0.001
Duration of drug use (oral/injecting)
Below 1 years 6.9 (4.6–8.8) 2.9 (1.6–4.8) <0.001 14.2 (11.1–17.2) 3.4 (2.2–4.8) <0.001
1–3  years 30.0 (26.8–34.1) 18.4 (15.4–21.9) 0.040 23.6 (20.4–26.9) 30.4 (26.6–33.8) 0.01
3–5  years 20.9 (17.5–23.6) 16.5 (13.5–18.9) <0.001 15.5 (13.3–18.2) 25.8 (23.5–29.2) <0.001
5+  years 42.2 (38.5–46.6) 62.2 (58.4–66.0) <0.001 46.8 (42.0–51.2) 40.4 (36.7–44.3) 0.03
Daily  injectors 48.3 (43.8–53.0) 57.3 (51.8–62.6) 0.01 41.1 (37.3–45.7) 21.7 (18.8–25.1) <0.001
Safe  injecting (last time) 90.3 (88.1–92.3) 96.3 (95.06–97.63)† – 80.2 (76.8–83.1) 80.82 (78.1–83.5)† –
Safe  injecting (consistent) 34.6 (30.3–38.3) 36.3 (32.2–40.1) 0.56 29.7 (25.8–33.3) 49.5 (45.9–53.0) <0.001
Condom use
Last time condom use with FSWs 81.4 (73.5–100.0)a 94.29 (90.39–98.18)b – 57.14 (37.60–76.68)c 67.35 (53.7–80.9)d –
Consistent condom use with FSWs 42.6 (33.8–71.1)a 31.0 (11.9–65.7)b 0.50 17.86 (02.73–32.98)c 28.57 (15.5–41.7)d –
Last  time condom use with regular
female partner
32.3 (21.8–40.6) 45.8 (40.0–53.7) 0.47 36.5 (32.7–41.7) 46.2 (39.1–50.6) 0.01
Consistent condom use with regular
female partner
2.4 (0.3–4.2) 7.0 (3.6–10.8) 0.14 4.3 (1.6–4.6) 13.1 (8.6–14.2) <0.001
Undergone HIV testing voluntary 15.6 (12.8–18.1) 38.2 (34.3–41.7) <0.001 3.9 (2.7–4.8) 15.0 (12.6–17.9) <0.001
Exposure of intervention
Contacted by PE/OW 46.7 (42.7–50.3) 54.2 (50.8–58.7) 0.01 21.8 (18.5–24.8) 43.1 (37.9–48.1) <0.001
Visited clinics 46.5 (41.7–50.3) 70.7 (66.6–74.4) <0.001 20.7 (17.6–23.7) 40.4 (34.7–46.1) <0.001
Received needle/syringe 54.9 (50.1–60.1) 60.2 (56.4–64.3) 0.11 18.5 (15.4–21.1) 42.1 (37.1–47.1) <0.001
Exposed to any of the three services 64.4 (60.2–69.0) 79.8 (74.9–82.7) <0.001 30.1 (26.4–33.8) 49.1 (43.2–54.6) <0.001
Biological variables
HIV-1 infection 27.8 (24.3–31.4) 29.2 (25.7–33.0) 0.59 1.4 (0.4–2.6) 1.6 (0.7–2.7) 0.82
Syphilis – reactive†† 4.0 (2.6–5.6) 3.3 (2.2–4.4) 0.05 12.0 (9.9–14.2) 14.8 (12.2–17.4) 0.10
Urethral gonorrhoea 0.2 (0.0–0.3) 0.4 (0.0–0.5) – 1.0 (0.3–1.7) 1.6 (0.7–2.6) 0.40
Urethral chlamydia 1.9 (1.1–2.7) 1.5 (0.7–2.4) 0.54 10.9 (8.6–13.2) 8.8 (6.8–10.7) 0.18
Hepatitis B reactive 6.1 (4.5–7.9) 10.7 (8.8–13.3) <0.001 5.6 (4.2–7.3) 8.1 (6.2–9.9) 0.05
Hepatitis C reactive 67.3 (63.0–72.0) 69.9 (65.5–74.2) 0.42 14.7 (11.6–17.2) 15.1 (12.3–17.8) 0.85
a,b,c,d Base are 80, 140, 29 and 49.
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†† Any person with a Reactive Plasma Reagent (RPR) and Treponema pallidum haem
BBA. While, the syphilis prevalence declined signiﬁcantly in Round
 compared with Round 1 (3% vs 4%, p = 0.05), the prevalence of HBV
ncreased in Round 2 compared with Round 1 (11% vs 6%, p < 0.001).
here was no signiﬁcant difference in other serological outcomes
Table 2). The prevalence of HIV in both rounds of IBBA was high and
id not show any signiﬁcant differences (27.8% in Round 1 vs 29.2%
n Round 2, p = 0.59) (Table 2). However, after adjusting for demo-
raphics and injection practices, we found that PWIDs in Round 2 of
he IBBA were signiﬁcantly less likely to be HIV infected compared
ith Round 1 (aOR: 0.48, 95% CI: 0.37–0.63; p < 0.01) (Table 3).
B) Nagalandrogramme coverage data
CMIS data showed that about 19% of the target PWIDs in Naga-
and (of the estimated denominator 8500 in the Avahan catchmentutination assay (TPHA).
in two  districts) had registered with the intervention in January
2005; this proportion increased to more than 80% by September
2009. We  also found that less than 1% of PWIDs had ever vis-
ited an Avahan clinic in March 2005; however, this proportion had
increased to 27% by March 2010. The proportion of PWIDs visiting
the clinic monthly, however, remained low at 11% in March 2010
(Fig. 2a). The ratio of active peer educator to number of PWIDs
was 1:93 in June 2005 and reached to 1:43 by June 2009 and
remained same till March 2010 (Fig. 2c). About two  free needles
and syringes were distributed per PWID/per month in June 2005
which increased to 11 per PWID/per month by March 2010.
A signiﬁcantly higher proportion of PWIDs reported having
been contacted by a peer educator/outreach worker, having vis-
ited Avahan clinics, or having received needles and syringes in
Round 2 compared with Round 1 in Nagaland (49% vs 30%, p < 0.001)
(Table 2).
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Table 3
Association between behavioural and biological outcomes, and two  rounds of the IBBA among People Who  Inject Drugs (PWIDs) in Manipur and Nagaland, India.a,b
Manipur, odds ratios (95% conﬁdence intervals) Nagaland, odds ratios (95% conﬁdence intervals)
Unadjusted Adjustedc Unadjusted Adjustedc
Injection practices
Consistent safe injection 1.07 (0.88, 1.32) 1.88 (1.46, 2.43)** 2.37 (1.94, 2.90)** 2.35 (1.86, 2.80)**
Safe injection last time† 3.69 (2.42, 5.61)** 3.83 (2.48, 5.92)** 1.05 (0.83, 1.34) 1.04 (0.80, 1.37)
Condom use with the regular female partner
Consistent condom use 1.77 (1.30, 2.42)** 1.57 (1.11, 2.23)** 1.58 (1.24, 2.01)** 2.09 (1.57, 2.80)**
Condom used last time 1.41 (1.03, 1.93)* 7.81 (0.75, 81.31) 2.40 (1.56, 3.71)** 3.38 (2.08, 5.52)**
Condom use with female sex workers
Consistent condom use 0.80 (0.61,1.04) 1.76 (0.78, 3.97) 0.32 (0.19, 0.55)** 1.87 (0.41, 8.53)
Condom used last time 8.17 (5.34, 12.48)** 8.47 (2.28, 31.43)** 1.75 (1.10, 2.78)** 2.23 (0.54, 9.17)
Biological outcomes
HIV-1 infection 1.06 (0.86,1.32) 0.48 (0.37, 0.63)** 1.27 (0.57, 2.85) 0.88 (0.35, 2.29)
Syphilis†† 0.82 (0.49,1.37) 1.77 (0.80, 3.92) 1.36 (1.03, 1.82)* 1.29 (0.937, 1.798)
Urethral chlamydia 0.77 (0.36,1.66) 0.78 (0.35, 1.74) 0.81 (0.60, 1.13) 0.83 (0.580, 1.198)
Hepatitis B 1.83 (1.29, 2.63)** 1.74 (1.16, 2.62)** 1.42 (0.98, 2.09) 1.05 (0.685, 1.610)
Hepatitis C 1.12 (0.92, 1.39) 0.80 (0.60, 1.08) 0.99 (0.76, 1.30) 0.70 (0.518, 0.953)
a The estimates shown here are weighted estimates (based on weight calculated by RDSAT for the dependent variable).
b The reference for each of the estimate is Round 1 of the IBBA. Thus, for consistent safe injection in the last six months the interpretation will be as follows: In Manipur,
after  adjusting, subjects in Round 2 of IBBA were signiﬁcantly more likely to report consistent safe injection compared with those in Round 1 of IBBA (aOR: 1.88, 95% CI: 1.46,
2.43).
c The models were adjusted for age, district of data collection, education, marital status, frequency of injection past month, duration of injection.
† Analysis on SPSS without using RDS weight.
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* p < 0.05.
** p < 0.01.
ocio-demographics
About 36% of the PWIDs were between the ages of 18 and 20
ears in Round 1 in Nagaland; however, the proportion in this age
ange had signiﬁcantly reduced to 18% in Round 2 (p < 0.001). The
roportion of literate PWIDs was high and similar in both rounds
f the IBBA in Nagaland. There was a signiﬁcant increase in the
roportion of PWIDs who were more than 31 years of age in Round 2
ompared with Round 1 (Table 2). The proportion of never married
nd married PWIDs increased in Round 2 compared with Round 1
Table 2). Select demographic characteristics of PWIDs in Nagaland
re described in Table 2.
ehavioural and biological data
rug injecting behaviours. The proportion of daily injectors reduced
igniﬁcantly in Round 2 compared with Round 1 (22% vs 41%,
 < 0.001). A lower proportion of PWIDs reported that they had
njected drugs for more than ﬁve years in Round 2 compared with
ound 1 (13% vs 21%, p < 0.001) (Table 2). Moreover, PWIDs were
ore likely to report ‘consistent safe injection practices’ in Round 2
ompared with Round 1 (aOR: 2.35, 95% CI: 1.86–2.80), even though
here was no signiﬁcant difference in the safe injection practice dur-
ng “last time” use (Table 3). In general, PWIDs who  were exposed
o various components of the Avahan intervention were less likely
o report unsafe injection practices (Table 4).
ondom use and other behaviours. PWIDs were more likely to report
onsistent condom use with a regular female partner (aOR: 2.09,
5% CI: 1.57–2.80) and condom use during the last sex act with
 regular female partner (aOR: 3.38, 95% CI: 2.08–5.52) in Round
 compared with Round 1. We  also found that PWIDs exposed to
he Avahan intervention were signiﬁcantly more likely to report
ondom use during the last sex act with a regular female part-
er in Round 2 compared with Round 1 (Table 4). Exposure to
vahan intervention was associated with a higher condom use
ith regular female partners and FSWs in both rounds of the IBBA
though in some cases the association was not statistically sig-
iﬁcant) (Table 4). Furthermore, PWIDs exposed to the Avahanintervention were signiﬁcantly more likely to have undergone an
HIV test in Round 2 compared with Round 1 (Table 4).
STIs and blood borne infections. The proportions of STIs in both
rounds of the IBBA varied and were not signiﬁcantly different
between the two rounds for most of the STIs (Table 2). The pro-
portion of HBV was  signiﬁcantly higher in Round 2 compared with
Round 1 (8% vs 6%, p = 0.05). However, after adjusting for demo-
graphic factors and injection practices, we found no signiﬁcant
differences between two rounds of IBBA in the likelihood of being
HBV positive (Table 3). The HIV prevalence was stable across both
rounds of the IBBA (1.2% in Round 1 and 1.6% in Round 2, p = 0.82)
(Table 2).
Discussion
The present assessment, using multiple data sources, provides
information on the Avahan intervention among PWIDs in Manipur
and Nagaland. The Avahan intervention was able to provide ser-
vices to the targeted 80% of the estimated PWID population in
its catchment area in both these states. There was a concomitant
improvement in access to services; during the course of the inter-
vention, the proportion of PWIDs accessing the clinic increased
in both Manipur and Nagaland. The intervention had distributed
free needles and syringes in these states, and safe injecting prac-
tices (such as never sharing needles/syringes) increased in these
states. Simultaneously, a higher proportion of PWIDs reported con-
sistent condom use with their regular female partners as well as
FSWs in Round 2. However, the HIV prevalence remained stable
in both states; and changes in the prevalence of STIs and blood
borne viral infections over time does not show any consistent
pattern.
An important achievement of the Avahan intervention was
the scale-up of services for targeted population of PWIDs in both
these states. Indeed, according to the technical guide by the World
Health Organisation, UNDOC, and UNAIDS (2009), this intervention
achieved a high target as far as coverage for PWIDs is concerned;
it could reach more than 60% of the estimated PWID population
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Table  4
Association between behaviours (injecting behaviours, condom use, and voluntary HIV testing) and exposure to various components of the Avahan intervention in Rounds
1  and 2 of the IBBA among People Who  Inject drugs Users (PWIDs) in Manipur and Nagaland, India.a
Manipur Nagaland
Adjusted ORb (95% CI) p-Value† Adjusted ORb (95% CI) p-Value†
IBBA Round 1 IBBA Round 2 IBBA Round 1 IBBA Round 2
Reported needle sharing behaviours
Shared needle/syringe at last injection 0.74 (0.53–1.04) 0.99 (0.51–1.91) 0.44 0.64 (0.43–0.94)* 0.58 (0.41–0.82)** 0.71
Shared  needle/syringe during past month 0.63 (0.46–0.87) ** 0.95 (0.65–1.39) 0.10 0.57 (0.37–0.85)** 0.53 (0.38–0.76)** 0.79
Used  drugs drawn from common container
at  last injection
1.61 (1.20–2.15)** 0.45 (0.33–0.62)*** <0.01 0.58 (0.40–0.86)** 0.96 (0.71–1.29) 0.04
Reported condom use behaviours
Condom used during last sex – regular
partnerc
1.17 (0.70–1.95) 1.71* (1.10–2.67) 0.27 1.27 (0.80–2.02) 2.36 (1.63–3.41)*** 0.04
Consistent condom use – regular partnerc 0.70 (0.16–3.02) 2.86* (1.03–7.92) 0.12 1.34 (0.48–3.78) 1.17 (0.70–1.97) 0.82
Condom used during last sex – female sex
workerd
1.06 (0.56–1.98) 0.34 (0.05–2.45) 0.28 1.56 (0.73–3.32) 27.1** (2.44–301.26) 0.03
Consistent condom use – female sex workerd 1.96 (0.36–10.42) 0.48* (0.24–0.99) 0.13 –†† 4.37 (0.81–23.60) –
Other  behaviours
Ever had a voluntary HIV test 2.63 (1.88–3.69)*** 2.26 (1.68–3.04)*** 0.51 1.82 (1.02–3.24)* 4.32 (2.99–6.24)*** 0.01
Note: Program exposure is deﬁned as; contact with peer educator, having received needles/syringes, AND having visited the clinic/drop-in centre.
a The reference for each of the estimate is not being exposed to that particular component of the programme. Thus, for shared needles/syringes at the last injection it will
be  as follows: in Manipur, subjects who were exposed to Avahan intervention in Round 1 of IBBA were signiﬁcantly less likely to report sharing needle/syringe at the last
injection compared with those unexposed (adjusted OR: 0.74, 95% CI: 0.53–1.04).
b Odds ratios were adjusted for age, literacy, duration of injecting, and frequency of injecting during the previous month.
c Analysis based on a subset of PWIDs; Round 1: 312 Manipur, 584 in Nagaland, Round 2: 388 in Manipur, 586 in Nagaland. Only participants who  responded as having a
regular  partner were included in these analyses.
d Analysis based on a subset of PWIDs; Round 1: 80 in Manipur, 28 in Nagaland, Round 2: 140 in Manipur, 49 in Nagaland. Only participants who responded as having
female sex workers as a sex partner were included in these analyses.
† The p value indicates the difference in ORs between two  rounds of IBBA.
†† Could not calculate due to small sample size.
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n both these states. Furthermore, the programme also success-
ully achieved a high target for distribution of free needles and
yringes to PWIDs in both these states. As seen in our assessment,
y steadily increasing the number of peer educators, and distribut-
ng free needles and syringes, Avahan was able to improve safe
njecting practices by PWIDs in these two states (particularly in
agaland) even in the existing difﬁcult socio-political environment
Chasie & Hazarika, 2009; Shimray, 2004). This achievement was
ue to intensive intervention combined with community based
nitiatives, such as mobilizing community to become members of
elf-help group or collectives. Thus, such an approach should be an
mportant component of HIV prevention in National HIV prevention
rogrammes (Armstrong, Kermode, Sharma, Langkham, & Crofts,
010; Kumar et al., 2009). Large scale HIV prevention interven-
ions by other programmes (such as Project ORCHID) in Manipur
nd Nagaland have also increased safe behavioural practices such
s reduced needle sharing and increased condom use (Armstrong
t al., 2010).
Some of the potential reasons for unsafe injecting practices
re: intermittent supply of needles and syringes by the inter-
ention programmes; structural issues such as unstable political
nvironment; harassment by law enforcement authorities; or low
evels of interest in the outreach workers (Chakrapani, Newman,
hunmugam, & Dubrow, 2011; Hangzo et al., 1997; Medhi et al.,
011). Additionally, interventions in the US and China (Fuller et al.,
007; Hammett et al., 2006; Rudolph et al., 2010; Wu et al., 2007)
ave used pharmacies and social marketing of injections to reduce
he injection risk behaviours among PWIDs; these could be poten-
ial interventions along with community based interventions for
isk reduction among PWIDs in India.An important aspect of developing interventions for PWIDs is
o address dual risk behaviours for HIV extending beyond nee-
le/syringe sharing to look at unprotected sex with various sexual
artners (Des Jarlais & Semaan, 2008; Eicher, Crofts, Benjamin,Deutschmann, & Rodger, 2000). Indeed, interventions with PWIDs
have not only resulted in safe injection practices but also safe
sex practices (Coyle, Needle, & Normand, 1998; Rotheram-Borus,
Rhodes, Desmond, & Weiss, 2010). In India, Panda et al. (2007)
have highlighted the importance of unsafe sex practices as a route
of transmission of STIs including HIV to PWIDs and their part-
ners. Solomon et al. (2011) found that the HIV prevalence among
a sample of PWIDs spousal partners in Chennai was  10 times
more than the prevalence in women  attending the antenatal clin-
ics. Thus, safe sex practices are important not only to reduce the
risk of acquisition of STIs and HIV among the male PWIDs  but
also to reduce the risk of transmission to their regular partners.
We found that consistent condom use with regular female part-
ners and FSWs increased from 2006 to 2009. Furthermore, PWIDs
who were exposed to components of the Avahan intervention were,
in general, more likely to use condoms with both regular female
partners and FSWs (even though some of the associations were
not statistically signiﬁcant). Thus, in these two states, in which the
Avahan intervention was initiated, there was  a reduction in multi-
ple risk behaviours – unsafe injecting practices and unsafe sexual
behaviour. Even though, opioid substitution therapy (OST) has been
implemented by various international funders and subsequently
the government in North-east of India (Armstrong et al., 2010;
Kumar et al., 2009), it was  not a part of the Avahan intervention.
It has been demonstrated that OST reduces high risk behaviours,
particularly injection practices, and HIV cases among PWIDs and
has also been suggested by UNAIDS, UNODC and the WHO  as an
intervention strategy (Gowing, Farrell, Bornemann, Sullivan, & Ali,
2008; World Health Organisation, et al., 2009). Thus, potentially,
addition of this intervention component may have increased safe
behaviours in our population. Another important intervention is
the use of pre-exposure prophylaxis (PreP) among PWIDs. In fact,
Alistar, Owens, and Brandeau (2014) reported that PreP can be an
additional important intervention strategy. They have also found
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hat it to be a cost-effective intervention, particularly in regions in
hich the main driver of epidemic is by injection drug use. How-
ver, pre exposure prophylaxis has still not been included in the
ntervention strategies in India.
The biological outcomes showed a mixed picture in our assess-
ent, and it also differed across both the states. For instance,
n Manipur the adjusted prevalence of HIV reduced in Round 2
hereas the prevalence of Hepatitis B increased. There were no
igniﬁcant differences in the prevalence of other STIs across both
ounds of the IBBA in Manipur. In Nagaland, there were no signif-
cant differences in any of the infections between the two rounds
f the IBBA. The HIV prevalence was relatively high in Manipur
hereas it was lower in Nagaland; these ﬁndings are similar to
hose reported by other authors (Mahanta et al., 2008; National
IDS Control Organisation, 2012). According to the 2010–2011 esti-
ates based on sentinel surveillance, NACO reported that the HIV
revalence showed a declining trend in both Manipur and Nagaland
National AIDS Control Organisation, 2012). Interestingly, in these
ata the estimated HIV prevalence was lower in Manipur (12.9%)
ompared with both rounds of the IBBA survey, whereas the esti-
ated HIV prevalence was higher in Nagaland (2.21%) compared
ith the IBBA survey. However, it should be noted that IBBA esti-
ates are based on data from only two districts in both the states
nd used a different methodology; we used RDS for sampling the
opulation for IBBA whereas surveillance data used facility based
esting. We  did ﬁnd that the HIV prevalence in Manipur was slightly
igher in Round 2 compared with Round 1 (29.2% vs 27.8%). How-
ver, after adjusting for age in the multivariate models, the odds
f being HIV infected was  lower in Round 2 (aOR: 0.48, 95% CI:
.37–0.63). Thus, potentially, the high HIV prevalence was  due to
he different age structures in both rounds of the IBBA in Manipur
a higher proportion of PWIDs were more than 31 years of age
n Round 2 compared with Round 1). HBV and HCV, the other
mportant infections transmitted by contaminated blood, also had
 relatively high prevalence in Manipur compared with Nagaland.
ahanta et al. (2009) found that PWIDs in Nagaland also had a
ower prevalence of these three infections compared with those in
ther north east states.
Armstrong et al. (2010) have highlighted the potential differ-
nces between the PWIDs in Manipur and Nagaland. According to
hem the reasons for these differences are the drug use patterns
nd the maturity of the AIDS epidemic (Armstrong et al., 2010).
or instance, the most common drug used in Nagaland is spasmo-
roxyvon, which may  also be used orally (Armstrong et al., 2010).
urthermore, Kermode et al. (2007) found that a majority of the
WIDs used heroin for ‘ﬁrst time injection’ in Manipur compared
ith Nagaland (48% vs 13%), whereas a majority of the PWIDs used
pasmoproxyvon for ‘ﬁrst time injection’ in Nagaland compared
ith Manipur (82% vs 49%). In addition to these differences in drug
se patterns, Armstrong et al. (2010) suggest that due to the mature
pidemic in Manipur, the response is equally effective; they high-
ight the fact that the HIV prevalence in Manipur has reduced from
0% in late nineties to 12% in 2007. Finally, Mahanta et al. (2008)
eported that PWIDs in Nagaland were more sexually active com-
ared with those in Manipur. It is quite likely that the HIV epidemic
n Nagaland may  be more due to sexual transmission rather than
njection drug use. In any case, PWIDs in both these states have a
igh prevalence of all three infections – HIV, HBV, and HCV. Thus,
hey should be the focus of HIV prevention and needle exchange
rogrammes.
It should be noted that the impact of intervention on chronic
nfections such as HIV, HBV, and HCV can be better assessed using
ncidence data. The prevalence may  reﬂect cumulative prevalence
nd in a short duration (of 3 years) a real decline in the prevalence
ay  not be visible. However, age-adjusted estimate of HIV preva-
ence shows a decline in Manipur in the second round that mayof Drug Policy 25 (2014) 853–864
indicate inﬂuence of intervention. Furthermore, although, there is
decline in high risk behaviours (injecting and sexual) in Round 2 in
both states, a large proportion of PWIDs still continues to engage in
high risk behaviours; therefore incidence of these infections (par-
ticularly STIs) may  still be high. Finally, we  can’t underestimate the
infection acquired through unsafe sex among PWIDs.
This assessment is not without its limitations. The Avahan
implementation and evaluation design did not include any con-
trol groups; thus it was not an ‘intervention-control two  group’
design. Rather, it was  a pre–post assessment. Ethically, it was  felt
by the programme designers that they could not withhold known
HIV prevention services to the PWIDs and could not have any con-
trol groups. Hence, a design that was  feasible and appropriate for
assessment for large scale public-health programmes was used
(Habicht, Victora, & Vaughan, 1999). It has been recommended
that in such a scenario, where multiple interventions are aiming
to reach vulnerable populations, evaluation designs using different
sources of evidence may  be used as an alternative to randomized
controlled trials (Bennett, Boerma, & Brugha, 2006; Bryce & Victora,
2005; Craig et al., 2008; Pettifor, MacPhail, Bertozzi, & Rees, 2007;
Victora, Black, Boerma, & Bryce, 2011). In our evaluation, multiple
sources of data helped triangulate our ﬁndings. It is quite likely that
some of the responses – particularly safe injection practices and
condom use – may  be inﬂuenced by social desirability bias and we
may  have overestimated these outcomes. It should be noted that
the impact of intervention on chronic infections such as HIV, HBV,
and HCV should ideally be assessed using incidence data (such as
those collected by cohort studies). Finally, IBBA data were collected
only among male PWIDs in four speciﬁc districts in the two states;
hence these ﬁndings may  not be generalizable to all the PWIDs in
Manipur and Nagaland. We  recruited only male PWIDs for IBBA
since earlier estimates showed that there were few female PWIDs
and we  did not have size estimates for the population. Furthermore,
intervention with female PWIDs was not an Avahan mandate.
In spite of these limitations, this assessment is an important con-
tribution to HIV prevention literature on PWIDs in India. It is one
of the few assessments of a large-scale HIV intervention on PWIDs
in India. Furthermore, our analyses based on the Avahan evalua-
tion design, present evidences along the program’s logic model.
We examined the coverage, outputs, and intermediate outcomes
followed by associations with program exposure. These analyses
were done using multiple data sources: program monitoring data
and independent survey data. Thus, these data provide evidence
for program effectiveness based on the congruency of ﬁndings in
these data sources (Habicht et al., 1999).
In conclusion, Avahan’s intervention programme for PWIDs in
Manipur and Nagaland met the ‘high-target’ goals for a scale-
up of coverage of services in geographically and socio-politically
challenging locations in North-east India. Some of the important
achievements of the Avahan intervention include: need based dis-
tribution of needles and syringes in these areas, increase in reported
safe injection practices, increase in reported consistent condom
use, and stabilization of HIV epidemic in these districts. Challenges,
however, remain about high HIV, HBV, and HCV prevalence among
these PWIDs in Manipur and Nagaland. Even though there is a
decline, the prevalence of high risk behaviours is high and remains a
concern. The high prevalence of STIs, particularly in Nagaland, high-
lights the need to focus on sexual transmission of infections among
PWIDs and their sexual partners. Thus, there is a need to maintain
the intensity of such targeted public health interventions (such as
outreach services, counselling services for HIV and STI prevention,
care, and treatment, provision of free new needle/syringe, abscess
management, clinic services for treating of sexually transmitted
infections, condom promotion and distribution and empowering
the community) – with addition of other components such as OST
and effective care of HIV infected PWIDs – to ensure high clinic
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